Arcede Pharma
Small, publicly listed pharmaceutical company focused on discovery and preclinical development of patent‑protected small‑molecule drug candidates for chronic respiratory diseases (COPD and severe asthma). Operates a virtual project model, outsources specialist capabilities, pursues patent protection, and seeks strategic partners for clinical development, manufacturing and commercialization. Headquartered in Lund, Sweden.
Industries
Nr. of Employees
small (1-50)
Patents
Products
RCD405 (lead preclinical drug candidate)
Lead small‑molecule candidate from the RESP9000 compound series prioritized for treatment of COPD and severe asthma; currently in preclinical development with toxicology studies initiated.
RESP3000 (PET imaging agent project)
Compound series developed for PET imaging to support cardiovascular diagnostics; project currently not actively pursued.
RESP1000 (historical compound series)
Earlier compound series with bronchodilatory and anti‑inflammatory properties; no active development currently.
RESP3000
A compound series of drug candidates with bronchodilatory and anti-inflammatory properties for the treatment of both COPD and asthma.
RESP1000
A compound series of drug candidates with bronchodilatory and anti-inflammatory properties for the treatment of both COPD and asthma.
RCD405
A pre-clinical drug candidate in the RESP9000 compound series developed for the treatment of COPD and severe asthma, demonstrating both anti-inflammatory and bronchodilatory properties.
RCD405 (lead preclinical drug candidate)
Lead small‑molecule candidate from the RESP9000 compound series prioritized for treatment of COPD and severe asthma; currently in preclinical development with toxicology studies initiated.
RESP3000 (PET imaging agent project)
Compound series developed for PET imaging to support cardiovascular diagnostics; project currently not actively pursued.
RESP1000 (historical compound series)
Earlier compound series with bronchodilatory and anti‑inflammatory properties; no active development currently.
RESP3000
A compound series of drug candidates with bronchodilatory and anti-inflammatory properties for the treatment of both COPD and asthma.
RESP1000
A compound series of drug candidates with bronchodilatory and anti-inflammatory properties for the treatment of both COPD and asthma.
RCD405
A pre-clinical drug candidate in the RESP9000 compound series developed for the treatment of COPD and severe asthma, demonstrating both anti-inflammatory and bronchodilatory properties.
Services
Structuring collaborations and license agreements in which strategic partners assume development, regulatory, manufacturing and commercialization responsibilities for lead candidates.
Structuring collaborations and license agreements in which strategic partners assume development, regulatory, manufacturing and commercialization responsibilities for lead candidates.
Expertise Areas
- Preclinical drug discovery
- Respiratory pharmacology
- Preclinical toxicology
- PET radiotracer development
Key Technologies
- Ex vivo airway tissue pharmacology assays
- In vivo pharmacology models (rodent and canine)
- PET imaging agent (radiotracer) development
- Preclinical toxicology studies
News & Updates
Multiple investor presentations and news items discussing preparations for Phase I, option exercises and fundraising activities.
Established in 2022 as a spin‑out from Respiratorius focused on respiratory drug projects.
Lead candidate RCD405 (RESP9000 series) prioritized for development; toxicology studies initiated as a milestone toward clinical development.
Company listed on the Spotlight Stock Market (public disclosures and investor documents available).
Multiple investor presentations and news items discussing preparations for Phase I, option exercises and fundraising activities.
Established in 2022 as a spin‑out from Respiratorius focused on respiratory drug projects.
Lead candidate RCD405 (RESP9000 series) prioritized for development; toxicology studies initiated as a milestone toward clinical development.
Company listed on the Spotlight Stock Market (public disclosures and investor documents available).